Difference between revisions of "Talk:Oroboros Laboratory"
From Bioblast
| Line 1: | Line 1: | ||
__TOC__ | __TOC__ | ||
== | == Picked up - reading and discussion == | ||
* 2017-06-08 '''Patent of Q-electrode (1988)''': Dr P.R. Rich, Glynn Res. Ph., Bodmin; European Patent no.85900699.1 [[User:Hungerm|Hungerm]] ([[User talk:Hungerm|talk]]) 10:18, 21 June 2017 (CEST) | * 2017-06-08 '''Patent of Q-electrode (1988)''': Dr P.R. Rich, Glynn Res. Ph., Bodmin; European Patent no.85900699.1 [[User:Hungerm|Hungerm]] ([[User talk:Hungerm|talk]]) 10:18, 21 June 2017 (CEST) | ||
| Line 11: | Line 11: | ||
* 2017-05-22: [[Komlodi 2017 Neuropharmacology]] | * 2017-05-22: [[Komlodi 2017 Neuropharmacology]] | ||
* ''' | * '''Various''' | ||
:::* [https://www.ncbi.nlm.nih.gov/pubmed/21664270 The rate of oxygen utilization by cells - interesting review beyond ascorbate topic] | :::* [https://www.ncbi.nlm.nih.gov/pubmed/21664270 The rate of oxygen utilization by cells - interesting review beyond ascorbate topic] | ||
:::* [http://time.com/4475628/the-new-science-of-exercise/ The new science of exercise] | :::* [http://time.com/4475628/the-new-science-of-exercise/ The new science of exercise] | ||
:::* [http://collections.plos.org/s/meta-research?utm_source=dfp&utm_medium=banner&utm_campaign=col-1604-metares Meta-research: Evaluation and improvement of research methods and practices] | :::* [http://collections.plos.org/s/meta-research?utm_source=dfp&utm_medium=banner&utm_campaign=col-1604-metares Meta-research: Evaluation and improvement of research methods and practices] | ||
== To our editors == | == To our editors == | ||
Revision as of 08:46, 22 June 2017
Picked up - reading and discussion
- 2017-06-08 Patent of Q-electrode (1988): Dr P.R. Rich, Glynn Res. Ph., Bodmin; European Patent no.85900699.1 Hungerm (talk) 10:18, 21 June 2017 (CEST)
- 2017-06-08 Pre-print publication: Mitochondria are physiologically maintained at close to 50 °C »Bioblast link«
- 2017-05-30 Quote of the day: ".. oligomycin (complex V inhibitor) determines the amount of ATP production is linked to respiration, FCCP (mitochondrial uncoupler) enables measurement of maximal respiratory capacity, while a combination of rotenone (complex I inhibitor) and antimycin A (complex III inhibitor) determines the reserved respiratory capacity." .. and more: "The mitochondrial network is a major site of ATP production through the coupled integration of the electron transport chain (ETC) with oxidative phosphorylation." - Trotta et al (2017) Disruption of mitochondrial electron transport chain function potentiates the pro-apoptotic effects of MAPK inhibition. JBC Papers in Press. Published on May 25, 2017 as Manuscript M117.786442.
- What is reserved respiratory capacity?
- 2017-05-22: Komlodi 2017 Neuropharmacology
- Various
To our editors
- >> Please check redirects from OROBOROS Mitochondrial Research Laboratory
- >> Please check redirects from OROBOROS MitoLab: visiting scientists
- Rationale: The 'MitoFit Centre of Excellence' or the 'MitoFit Core Facility' will be comprise of the OROBOROS MitoFit Laboratory and the DSL MitoFit Facility.
